What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Quantexa announced a $175 million Series F on March 5, 2025, led by Teachers’ Venture Growth, the investment arm of Ontario Teachers’ Pension Plan. Quantexa said the round valued the private company at $2.6 billion. The funding is intended to expand its enterprise Decision Intelligence software, customer work, partnerships and North American business.
Who led Quantexa’s Series F, and what are the terms?
Teachers’ Venture Growth (TVG) led the round. Quantexa named existing investors Warburg Pincus, Dawn Capital, BNY, Evolution Equity Partners, AlbionVC, HSBC and British Patient Capital as participants. Separately, British Patient Capital announced a £15 million follow-on investment. TVG Managing Director Ara Yeromian was expected to join Quantexa’s board, subject to regulatory approval.
Quantexa stated the $2.6 billion valuation for the financing; TechCrunch independently reported the same post-money figure and noted that Quantexa had been valued at $1.8 billion in its 2023 Series E. These are private-company transaction valuations, not public share prices. Quantexa’s Series F announcement, British Patient Capital’s investment announcement and TechCrunch’s round coverage describe the financing.
What does Quantexa do?
Quantexa sells enterprise software built around what it calls Decision Intelligence. Its platform is designed to bring together information spread across disconnected systems, link people, organizations and other entities, and put those relationships into context for operational decisions. The company identifies data management, customer intelligence, know-your-customer (KYC), anti-money-laundering (AML), financial crime, fraud, risk and security as areas it serves.
For example, an organization investigating suspected fraud may need to connect records that sit in separate databases or use different formats. Quantexa’s proposition is that linking entities and relationships can help investigators and other teams work with that information in decision workflows. The company also argues that well-curated, trustworthy data is a foundation for AI projects. That is a rationale for its product strategy, not a guarantee that AI systems using the platform will be accurate, safe or free from bias.
Why is the company raising money for AI-related work?
Quantexa’s established business areas include financial crime, AML, KYC, fraud and risk. The company and TechCrunch have also described an effort to apply its data-linking and curation capabilities to wider analytics and AI work. The strategic connection is straightforward: AI services need usable data, and organizations often have relevant information split across systems. Connecting and contextualizing that information may help prepare it for analytics, but the funding announcement does not establish that Quantexa’s tools alone solve data quality or AI governance problems.
Quantexa’s March 2025 announcement cited work with Microsoft on an AI workload for Microsoft Fabric and a cloud-native AML solution for U.S. mid-market banks through Azure Marketplace. In 2024, the company also announced partnership agreements with Microsoft and Databricks. TechCrunch reported plans for further work in the Databricks environment. These are company and media descriptions of partnerships or planned products; they do not independently establish customer adoption, product availability in every market, or performance results. See Quantexa’s round announcement, its 2024 operating-milestone announcement and TechCrunch’s report.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitchesHow Quantexa said it would use the funding
At the time of the announcement, Quantexa said the proceeds would support:
- Platform innovation and improvements to the client experience.
- Partnerships and alliances.
- Expansion in North America.
- Selected mergers and acquisitions.
Those were stated intentions, not confirmation that the spending or acquisitions had already occurred.
What growth figures has Quantexa reported?
The available figures below come from Quantexa or, for one performance claim, British Patient Capital’s reproduction of the company description. They should be read as attributed claims rather than independently audited comparisons.
| Figure | What it refers to | Attribution and qualification |
|---|---|---|
| More than $100 million ARR | Annual recurring revenue milestone | Quantexa reported it in October 2024 and said it qualified the company for “Centaur” status. Company announcement. |
| Nearly 40% license-revenue growth; 23 new customers | Growth and customers added in 2024 | Quantexa’s 2025 Series F announcement; the release did not provide an independent audit of these figures. Company announcement. |
| 16 offices; more than 800 employees | Company footprint and workforce | Quantexa’s 2025 Series F announcement. Company announcement. |
| 30 top-tier global clients; more than 50% of new Decision Intelligence ARR from existing customer relationships | Customer and revenue indicators | Quantexa reported these figures in 2024, describing clients gained since the start of its fiscal year. Company announcement. |
| 30% of Decision Intelligence revenue origination outside financial services; customers in more than 100 countries | Business mix and geographic reach | Quantexa-reported figures from its 2024 announcement. Company announcement. |
| Over 90% more accuracy; 60 times faster analytical-model resolution | Comparison with traditional approaches | British Patient Capital reproduced these claims in a description of Quantexa; the cited text does not provide a methodology to assess them independently. British Patient Capital announcement. |
| 228% ROI over three years | Economic impact | Described by British Patient Capital as a finding from an independently commissioned Forrester Total Economic Impact study. The cited description does not state the study’s year. British Patient Capital announcement. |
What the funding and valuation do—and do not—show
The Series F indicates that major investors committed new capital to Quantexa and that the company plans to invest in product development, customers, partnerships and expansion. The announced valuation provides a transaction benchmark for a private company, not a readily tradable price or proof of future business performance.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchLikewise, the growth and product-performance figures are useful context for understanding Quantexa’s own account of its scale, but company-reported metrics and reproduced claims are not equivalent to independent head-to-head tests. The cited announcements do not provide competitor pricing or comparative testing sufficient to establish that Quantexa is the best option for a particular enterprise.
Is Quantexa a product for individual users?
No. The sources describe an enterprise software company and work involving organizations, financial institutions and cloud platforms; they do not present a consumer product or a buying offer for individuals.
Quantexa’s press index listed company announcements through October 1, 2026, when accessed October 4, 2026. That index is useful for checking newer company news, but it does not independently verify the Series F terms or establish whether the March 2025 financing remains its latest capital event across all databases. Funding, valuation, headcount and product availability can change. Quantexa’s press-release index.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
